Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update

08:01 EST 15 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
– Generated 2017 revenue of $298 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $701 million and expansion of LINZESS commercial margin to 61% – – On track to advance key pipeline candidate...

Other Sources for this Article

Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Vice President, Investor Relations and Corporate Communications


More From BioPortfolio on "Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...